Lansoprazole Capsule, Delayed Release
Product Images NDC 70700-262

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 70700-262). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xiromed Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle-label-15mg.jpg (Bottle Label 15mg)

Label for Lansoprazole Delayed-Release Capsules USP 15 mg by Xiromed LLC. The label indicates each capsule contains 15 mg of Lansoprazole, with a package of 30 capsules. Instructions include medication guide dispensing, storage at 20° to 25°C, and a US pharma regulation note. The product is made in Spain and has an NDC code 70700-262-30.*

FDA Label Image

Bottle-label-30mg.jpg (Bottle Label 30mg)

Lansoprazole Delayed-Release Capsules USP 30 mg label showing the drug name, strength, and dosage form. The label indicates a 30-capsule count, prescription-only status, manufacturer Xiromed LLC, and storage instructions at 20° to 25°C (68° to 77°F). It includes usage directions to see the package insert for dosing information and cautions to keep out of reach of children.*

FDA Label Image

Figure-1.jpg (Figure 1)

A line graph depicting the mean severity of day heartburn over study days for evaluable patients, comparing placebo, Lansoprazole 15 mg QD, and Lansoprazole 30 mg QD. The y-axis measures mean severity of day heartburn from 0 (none) to 3 (severe), and the x-axis shows days from start of treatment ranging from -5 to 60. Lansoprazole groups show reduced heartburn severity compared to placebo over time.*

FDA Label Image

Figure-2.jpg (Figure 2)

A line graph titled 'Mean Severity of Night Heartburn By Study Day For Evaluable Patients' showing mean severity scores over 60 days from start of treatment. The graph compares three groups: Placebo, Lansoprazole 15 mg QD, and Lansoprazole 30 mg QD. The severity scale ranges from 0 (None) to 3 (Severe).*

FDA Label Image

Formula-structure.jpg (Image 01)

Chemical structure diagram of lansoprazole showing its molecular components, including the benzimidazole and pyridine rings with associated functional groups such as sulfoxide and trifluoromethoxy moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.